Ambeed.cn

首页 / / / / 4”-O-Glucosylvitexin

4”-O-葡萄糖基牡荆素 /4”-O-Glucosylvitexin 99%+

货号:A108675 同义名: 4″-O-牡荆素葡萄糖苷 / Glucosylvitexin Ambeed 开学季,买赠积分,赢豪礼

Vitexin-4″-O-Glucoside can inhibit TPO activity. It is a natural product isolated and purified from the fruit of Crataegus pinnatifida Bge.

4”-O-Glucosylvitexin 化学结构 CAS号:123063-33-2
4”-O-Glucosylvitexin 化学结构
CAS号:123063-33-2
4”-O-Glucosylvitexin 3D分子结构
CAS号:123063-33-2
4”-O-Glucosylvitexin 化学结构 CAS号:123063-33-2
4”-O-Glucosylvitexin 3D分子结构 CAS号:123063-33-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

4”-O-Glucosylvitexin 纯度/质量文件 产品仅供科研

货号:A108675 标准纯度: 99%+
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell,2024. Ambeed. [ A125712 ]
Cancer Discov., 2024. Ambeed. [ A285925 ]
JMC, 2024. Ambeed. [ A288696 ]
JMC, 2024. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >

4”-O-Glucosylvitexin 生物活性

描述 Vitexin-4″-O-glucoside (VOG), being a main component in the leaves of Crataegus pinnatifida Bge. Vitexin-4″-O-Glucoside (VOG) can inhibit TPO activity. It is a natural product isolated and purified from the fruit of Crataegus pinnatifida Bge. Additionally, α half-life, β half-life, (a)CL, MRT(0→t ), MRT(0→∞ ), and terminal half-life of VOG in rats showed significant differences between 20 mg/kg and other doses. Thereby, VOG presented a dose-dependent pharmacokinetics in the range of 20-60 mg/kg and non-linear pharmacokinetics at lower dose[3]. In addition, VOR (Vitexin-2"-O-rhamnoside) and VOG caused no cytotoxic effect on hADSCs (human adipose-derived stem cells) at concentrations up to 250 and 480 μm, respectively. Both VOR and VOG contribute to the protection against H2 O2 -mediated oxidative stress damage and could be safely used for a wide range of concentrations[4]. Renal excretion was the dominant path of elimination of VOG for oral and intravenous administration in mice and biliary excretion contributed less[5].

4”-O-Glucosylvitexin 参考文献

[1]Wu LZ, Zhang XP, et al. Characterization of aromatic glycosides in the extracts of Trollius species by ultra high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. J Pharm Biomed Anal. 2013 Mar 5;75:55-63.

[2]Gaitan E, Lindsay RH, et al. Antithyroid and goitrogenic effects of millet: role of C-glycosylflavones. J Clin Endocrinol Metab. 1989 Apr;68(4):707-14.

[3]Ying XX, Wang F, Cheng ZZ, Zhang WJ, Li HB, Du Y, Liu X, Wang SY, Kang TG. Pharmacokinetics of vitexin-4″-O-glucoside in rats after intravenous application. Eur J Drug Metab Pharmacokinet. 2012 Jun;37(2):109-15

[4]Wei W, Ying X, Zhang W, Chen Y, Leng A, Jiang C, Liu J. Effects of vitexin-2"-O-rhamnoside and vitexin-4"-O-glucoside on growth and oxidative stress-induced cell apoptosis of human adipose-derived stem cells. J Pharm Pharmacol. 2014 Jul;66(7):988-97

[5]Cai S, Chen Y, Zhang W, Ying X. Comparative study on the excretion of vitexin-4''-O-glucoside in mice after oral and intravenous administration by using HPLC. Biomed Chromatogr. 2013 Nov;27(11):1375-9

4”-O-Glucosylvitexin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.64mL

0.33mL

0.16mL

8.19mL

1.64mL

0.82mL

16.38mL

3.28mL

1.64mL

4”-O-Glucosylvitexin 技术信息

CAS号123063-33-2
分子式C27H30O16
分子量 610.518
别名 4″-O-牡荆素葡萄糖苷 ;Glucosylvitexin
运输蓝冰
存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 250 mg/mL(409.49 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。